Rheumazentrum Ruhrgebiet, Herne, and Ruhr-Universität Bochum, Germany.
Clin Exp Rheumatol. 2013 Jul-Aug;31(4 Suppl 78):S33-6. Epub 2013 Oct 3.
Remission has not been a major topic in ankylosing spondylitis (AS) in recent years but there is now increasing interest in analogy to rheumatoid arthritis (RA). RA and AS are chronic inflammatory diseases with more differences than similarities. New classification criteria for axial spondyloarthritis (axSpA) have recently added patients with so called non-radiographic axSpA to the spectrum, hereby including earlier disease stages without structural changes. Therapeutic strategies include non-steroidal anti-inflammatory agents (NSAIDs) and biologics, mainly anti-TNF agents. Both work rather well for signs and symptoms, and possibly also for structure modification. Discontinuation of anti-TNF agents has been a major topic in RA in the last 2 years. In axSpA there has been less enthusiasm because early reports have been rather discouraging. However, no prospective controlled trials have been performed. This is a clear unmet need which should be addressed in future trials.
缓解在近年来并非强直性脊柱炎（AS）的主要话题，但现在人们对其与类风湿关节炎（RA）的类比越来越感兴趣。RA 和 AS 是慢性炎症性疾病，其差异多于相似之处。轴性脊柱关节炎（axSpA）的新分类标准最近将所谓的非放射学 axSpA 患者纳入其中，从而包括了没有结构变化的更早的疾病阶段。治疗策略包括非甾体抗炎药（NSAIDs）和生物制剂，主要是抗 TNF 制剂。这些药物对症状和体征都有很好的疗效，可能对结构改变也有疗效。在过去的 2 年中，RA 中停用抗 TNF 制剂一直是一个主要话题。在 axSpA 中，人们的热情较低，因为早期的报告令人沮丧。然而，尚未进行前瞻性对照试验。这是一个明确的未满足的需求，应该在未来的试验中解决。
